A new study by an international team, co-led by Dr. Gerhard Koenig from the University of Portsmouth, tackled the problem of antibiotic resistance by redesigning existing antibiotics to overcome bacterial resistance mechanisms. The research is published in PNAS.
About 700,000 people are estimated to die every year because of antibiotic-resistant bacteria, and that number is expected to rise to millions.
Without effective antibiotics, life expectancy is predicted to drop by 20 years.
The race has been on for many years to develop new antibiotics to fight disease faster than a disease can evolve.
Computers have been used in drug design for decades, but this is the first study to use a multi-pronged computer-guided strategy to make a new antibiotic from an existing one which bacteria have outwitted.
Dr. Koenig, a computational chemist and first author on the paper, said: “Antibiotics are one of the pillars of modern medicine and antibiotic resistance is one of the biggest threats to human health. There’s an urgent need to develop new ways of fighting ever-evolving bacteria.
“It’s only a matter of time until bacteria develop counterstrategies against our counterstrategies and become resistant to the new antibiotic, so we will have to keep on studying bacterial resistance mechanisms and develop new derivatives accordingly.”
The hope of this new work lies in showing that the resistance mechanisms of bacteria can be addressed in a systematic way, allowing science to continually fight back with a computational evolution of new antibiotics.
Dr. Koenig said: “Our computers are becoming faster with every year. So, there is some hope that we will be able to turn the tide.
“If computers can beat the world champion in chess, I don’t see why they should not also be able to defeat bacteria.”
The international team, including Nobel Prize laureate Ada Yonath, carried out the research at the Max-Planck-Institut für Kohlenforschung, the Weizmann Institute, and the universities of Duisburg-Essen, Bochum and Queensland.
They developed a strategy to simulate many aspects of a redesigned antibiotic at the same time, including how soluble it is, how effective it is at entering into the bacteria, and how efficient it is at blocking their protein production.
The computational work outlined in the research was done in a matter of weeks on one of the top supercomputers in Europe, but it took the international team several years to verify experimentally that their approach was indeed correct.
Dr. Koenig said: “Using a computational approach makes the development of new antibiotic derivatives faster and cheaper, and predicting whether a chemical compound is going to be active before it is synthesised also avoids chemical waste.
“This is an extremely empowering technology.”
“Developing a new antibiotic usually involves finding a new target that is essential for the survival of a wide range of different bacteria. This is extremely difficult, and only very few new classes of antibiotics have been developed in recent times.
“We have taken a simpler approach by starting from an existing antibiotic, which is ineffective against new resistant strains, and modifying it so it’s now able to overcome resistance mechanisms.”
The team has shown that their best drug candidate, which is yet to undergo clinical trials, is up to 56 times more active for the tested bacterial strains than two antibiotics on the World Health Organisation’s (WHO) list of essential medicines, erythromycin and clarithromycin.
Dr. Koenig said: “Not only is our best candidate more effective against the tested targets, but it also shows activity against the three top-ranked bacteria from the WHO priority list where the tested existing antibiotics don’t work.
The international team, including Nobel Prize laureate Ada Yonath, carried out the research at the Max-Planck-Institut für Kohlenforschung, the Weizmann Institute, and the universities of Duisburg-Essen, Bochum and Queensland.
